Find Clinical Trials

Inclusion Criteria: * T2D * Diabetes duration of ≥12 months * ≥18 years of age * HbA1c ≥58 mmol/mol * Attending the SDCC outpatient clinic * Provided voluntary signed informed consent. Exclusion Criteria: * Inability to understand the patient information. * Complications which do not permit to lowering HbA1c to \<58 mmol/mol. * Treatment with insulin. * Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion. * Systematic use of corticosteroids. * Using or requiring a specialized diet (e.g., kidney diet). * Circumstances that affect HbA1c (e.g., liver disease and anaemia). * Known or suspected drug or alcohol abuse (judged by the investigator). * Pregnancy or breastfeeding or plans of pregnancy within the study period. * Participation in other clinical trials.

Inclusion Criteria: * Patients aged 19 years or older and under 80 years. * Patients with liver function are classified as Child-Pugh Class A. * Barcelona Clinic Liver Cancer stage C patients with no prior systemic anticancer therapy for hepatocellular carcinoma. * Patients with an Eastern Cooperative Oncology Group performance score of 0-1. * Adequate Hematologic and Liver Function: A. Hemoglobin: ≥ 9.0 g/dL B. Absolute Neutrophil Count : ≥ 1,000/mm³ C. Platelet Count: ≥ 70,000/μL D. Prothrombin Time: ≥ 70% (or Prothrombin Time INR ≤ 1.2) * Patients with upper gastrointestinal endoscopy performed within six months prior to the start of anticancer treatment. * No plans for breastfeeding, and if of childbearing potential, using contraception or no plans for spouse's pregnancy or practicing contraception. * Patients who have received an explanation of the treatment purpose and methods and have provided informed consent for the treatment. Exclusion Criteria: * Participants who have previously received systemic anticancer therapy for advanced hepatocellular carcinoma. * Patients with intrahepatic tumor involvement of 50% or more. * Patients with tumor thrombus in the main portal vein or both first-order branches (Vp4). * Patients with a prior history of liver transplantation. * with uncontrolled malignant tumors other than HCC at the time of enrollment (participation is allowed if disease-free survival exceeds two years). * Patients with uncontrolled or serious underlying diseases requiring treatment. * Patients with a history of esophageal or gastric variceal bleeding. * Previous Variceal Treatments: Patients who have undergone any of the following treatments for variceal bleeding: A. Endoscopic Variceal Obliteration (EVO) B. EVL C. Transjugular Intrahepatic Portosystemic Shunt (TIPS) D. Percutaneous Approach for Retrograde Transvenous Obliteration (PARTO) E. Surgical procedures * Patients who have used anticoagulants or antiplatelet agents within one week prior to the study. * Presence of grade 2 or higher isolated gastric varices or Red Color Signs confirmed by baseline endoscopy (EGD). * Patients who are pregnant. * Patients who are unable to understand or provide written informed consent. * Patients deemed unsuitable for clinical study participation based on the investigator's judgment.

Inclusion Criteria: 1\. Pathological diagnosis of stage I-III breast cancer (non-T4), \>18 years old; 2. Complete breast cancer resection (including skin-sparing and nipple-sparing total resection) 3. According to the guidelines of the Chinese Anticancer Society, postoperative adjuvant radiotherapy is required; 4. Undergo immediate reconstructive surgery (tissue dilator or permanent implant) Exclusion Criteria: 1. Auto-reconstruction surgery 2. Clinical or pathological T4 3. Both sides need radiotherapy 4. Have a history of chest radiotherapy 5. Pregnancy/lactation 6. Participate in other drug clinical trials

Inclusion Criteria: * Participants who require transjugular intrahepatic portosystemic shunt (TIPS) and meet the clinical indications for the procedure. * Participants whose physical condition is suitable for TIPS. Exclusion Criteria: * Participants with a history of allergy or serious adverse reactions to iodine contrast media or other related drugs. * Participants are pregnant or breastfeeding. * Participants are unwilling or unable to sign informed consent.

Inclusion Criteria: * Male and female volunteers * 18 years of age or older * Assessed for a severe asthma exacerbation * Being prescribed OCS for the management of their exacerbation * Able to comprehend and follow all required study procedures * Able to understand and give written informed consent and have signed a written informed consent form (ICF) approved by the REB Exclusion Criteria: * For females, are pregnant, or lactating * Respiratory comorbidities other than asthma, including bronchiectasis (non-CF) or asthma-COPD overlap (ACO) * FEV1 \<40% of personal best or \<1 Li * OCS-dependent * Asthma exacerbation in the 4 weeks preceding the study visit * Concomitant disease, health condition, and/or lifestyle activities that could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease. These include, but are not restricted to: heart failure, previous bipolar decompensation with prednisone, severe blood hypertension, uncontrolled diabetes, pneumonia. * Unwilling or unable to comply with the study protocol for any other reason

Inclusion Criteria: 1. Signed written informed consent 2. ≥18 years of age 3. Histologically or cytologically confirmed HER2 negative breast cancer for whom IV paclitaxel monotherapy has been recommended. 4. HER2 negative per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guideline. Subjects can be estrogen receptor/progesterone receptor (ER/PR) positive or negative per ASCO CAP guideline, but ER/PR and HER2 receptor status must be known. 5. Metastatic breast cancer with target lesions measurable by CT scan per RECIST v1.1 criteria confirmed by BICR 6. Adequate hematologic status as demonstrated by not requiring granulocyte colony stimulating factor (G CSF) or transfusion support within 30 days prior to randomization to achieve the following at screening: * Absolute neutrophil count (ANC) ≥1500/mm3 * Platelet count ≥100,000/mm3 * Hemoglobin ≥9 g/dL 7. Adequate liver function as demonstrated by: * Total bilirubin ≤upper limit of normal (ULN) unless the subject has Gilbert's disease, for which bilirubin must be ≤2.0 × ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 × ULN 8. Adequate renal function as demonstrated by estimated glomerular filtration rate (eGFR) ≥60 mL/min 9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 10. Life expectancy at least 6 months, in the judgment of the Investigator 11. Female subjects must be postmenopausal (≥12 months without menses) or surgically sterile (ie, by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or must be using effective contraception (ie, non-hormonal intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment. 12. Women of childbearing potential must have a negative screening serum pregnancy test and urine test within 4 days prior to start of dosing in the study and not be breast feeding. 13. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of investigational product (IP). Exclusion Criteria: 1. Not recovered to ≤grade 1 toxicity from previous anticancer treatments or previous investigational product (IP) except alopecia 2. QTcF interval ≥470 msec at baseline 3. Relapsed less than 6 months following treatment with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease 4. Known active central nervous system metastasis, including leptomeningeal involvement 5. Currently receiving other medications intended for the treatment of their malignancy 6. Received other IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer 7. Received biologics or monoclonal antibodies intended for the treatment of their malignancy within 30 days of the first study dosing day 8. Received radiation therapy within 2 weeks prior to signing informed consent or radiation therapy is planned within 6 months from the time of signing informed consent 9. Taking a medication known to be a moderate or strong cytochrome P450 (CYP) 3A4 inhibitor or inducer or neurokinin-1 receptor antagonist (NK-1) inhibitor within 14 days prior to start of dosing in the study 10. Taking a medication known to be a moderate or strong CYP2C8 inhibitor or inducer within 14 days prior to start of dosing in the study 11. Taking an oral medication with a narrow therapeutic index known to be a P-glycoprotein (P-gp) substrate within 24 hours prior to start of dosing in the study 12. Taking a medication known to be a P-gp inhibitor or inducer within 14 days prior to start of dosing in the study 13. Taking a medication known to be an organic anion transporting polypeptide 1B1/3 (OATP1B1/3) inhibitor 14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements 15. Major surgery to the upper GI tract, inability to take oral medication, or have a history of GI disease or other medical condition that, in the opinion of the Investigator may interfere with oral drug absorption 16. History of significant hypersensitivity-type reaction to paclitaxel or Cremophor EL that would contraindicate the use of IV paclitaxel 17. Known allergic reaction or intolerance to contrast media 18. Documented history of true systemic allergic reaction to 3 or more medications 19. Active hepatitis B (as evidenced by being HBsAg positive) or active hepatitis C (HCV-RNA positive) or cirrhosis of the liver 20. Known HIV infection 21. The Investigator believes that participation in this study would not be acceptable

3.1 Inclusion Criteria Subjects must meet all of the following criteria to be eligible: Age and gender: Female, ≥18 years old. Histopathological confirmation: Invasive breast cancer confirmed by histopathology. No prior systemic anti-tumor therapy for breast cancer. Triple-negative PD-L1-positive breast cancer: ER/PR-negative (IHC nuclear staining \<10%). HER2-negative (IHC 0/1+ without FISH testing or IHC 2+ with FISH-negative amplification). PD-L1 Combined Positive Score (CPS) ≥1. Tumor stage: T1c-T2, N0-1 or T1a-T1b, N1 (per AJCC 8th Edition criteria). Measurable lesion: At least one measurable target lesion per RECIST v1.1. ECOG performance status: 0-1. Life expectancy: ≥3 months. Adequate organ and bone marrow function (within 1 month prior to treatment, without corrective therapy within 14 days before first dose): Bone marrow: Absolute neutrophil count (ANC) ≥2.0 ×10\^9/L. Platelets ≥100 ×10\^9/L. Hemoglobin ≥100 g/L. Liver/kidney function: Albumin ≥3.0 g/dL. Total bilirubin \<1.5 × ULN. ALT/AST \<1.5 × ULN. Alkaline phosphatase ≤2.5 × ULN. BUN and serum creatinine \<1.5 × ULN or creatinine clearance \>60 mL/min (Cockcroft-Gault formula). Coagulation: PT and APTT ≤1.5 × ULN. Cardiac function: LVEF ≥55% by echocardiography (ECHO). QT interval: QTcF ≤470 ms. Reproductive status: Premenopausal women: Negative serum pregnancy test within 14 days before treatment. Non-lactating. All subjects must use effective barrier contraception during treatment and for 6 months post-treatment. Informed consent: Willing to sign informed consent and comply with study procedures. 3.2 Exclusion Criteria Subjects meeting any of the following criteria will be excluded: Unconfirmed diagnosis: Breast cancer not histopathologically confirmed. Specific subtypes: Bilateral, inflammatory, or occult breast cancer. Metastatic disease: Evidence of metastatic breast cancer (excluded via chest/abdominal CT and bone scan; PET/CT allowed as alternative). Prior anti-tumor therapy: Chemotherapy, radiotherapy, targeted therapy, or endocrine therapy for breast cancer. Curative radiotherapy within 4 weeks or palliative radiotherapy within 2 weeks before first dose. Prior immunotherapy: Anti-PD-1, anti-PD-L1, anti-PD-L2, or other immune checkpoint inhibitors. Concurrent anti-tumor therapy: Any other anti-cancer treatments during the study. Second primary malignancy: Except adequately treated non-melanoma skin cancer. Transplant history: Prior organ or bone marrow transplantation. Recent clinical trials: Participation in another drug trial within 4 weeks prior to enrollment. Immunosuppressive therapy: Systemic corticosteroids (\>10 mg/day prednisone equivalent) or immunosuppressants within 2 weeks before first dose (excluding inhaled/topical steroids). Vaccination: Live or attenuated vaccines within 4 weeks before first dose. Major surgery: Non-breast-related major surgery within 4 weeks before first dose or incomplete recovery. Autoimmune diseases: Active autoimmune disease or history of autoimmune disease with potential recurrence (e.g., autoimmune hepatitis, uveitis, thyroid dysfunction requiring systemic treatment). Exceptions: Vitiligo, psoriasis, alopecia, controlled childhood asthma, or type 1 diabetes managed with insulin. Immunodeficiency: HIV-positive, congenital/acquired immunodeficiency disorders. Cardiovascular disease: History within 6 months: Myocardial infarction, stroke (excluding lacunar infarct), pulmonary embolism, unstable angina, NYHA Class III/IV heart failure. Clinically significant arrhythmia, primary cardiomyopathy, atrial fibrillation (EHRA ≥2b), uncontrolled hypertension, or QTcF \>470 ms. Pulmonary disease: Interstitial lung disease, idiopathic pulmonary fibrosis, severe COPD/asthma, or autoimmune/collagen vascular diseases with pulmonary involvement. Infections: Active hepatitis B (HBsAg+ with HBV DNA ≥500 IU/mL), hepatitis C (HCV RNA \> ULN), cirrhosis, or severe infections requiring antimicrobial therapy. Bleeding/thrombosis disorders: Hereditary/acquired bleeding or thrombotic tendencies (e.g., hemophilia). Hypersensitivity: Allergy or contraindication to study drug components. Pregnancy/lactation: Pregnant, breastfeeding, or unwilling to use contraception. Comorbidities: Uncontrolled conditions (e.g., hypertension, diabetes, active infections) contraindicating ADC or PD-L1 inhibitors. Neurological/psychiatric disorders: Epilepsy, dementia, or other conditions deemed unsuitable by the investigator.

Inclusion Criteria: * 18 years of age or older * Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications * Written informed consent signed from subject prior to performing any protocol-related procedures Exclusion Criteria: * Use of any investigational agent within 14 days prior first visit; * Patient under guardianship/trusteeship or legally incapacitated person; * Patient unable to understand read and/or sign an informed consent; * Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties; * Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme; * Patients who are known to be HIV positive

Inclusion Criteria: 1. Aged 14-60 years (including 14 and 60), no gender restriction; 2. HAMD \>= 14; 3. Written informed consent obtained from the patient; written informed consent obtained from the guardian for minors. Exclusion Criteria: * Persons with severe suicidal tendencies (item 10 of the MADRS scale ≥ 5).

Inclusion Criteria: 1. Understand the study process, participate in the study voluntarily, and sign the informed consent form. 2. patients with histopathologically confirmed initial unilateral primary invasive breast cancer, occult breast cancer, Patients with histopathologically confirmed initial unilateral primary invasive breast cancer, with the exception of occult breast cancer, inflammatory breast cancer and eczema-like carcinoma 3. aged ≥ 18 years and ≤ 60 years, female 4. patients who meet the inclusion criteria for neoadjuvant therapy to receive neoadjuvant therapy for breast cancer (locally advanced) Patients with locally advanced breast cancer (AJCC stage III, except T3N1M0) or operable breast cancer, but without breast-conserving or axillary preservation (stage IIA-IIB and T3N1M0) or HER2 positive or TNBC with certain tumour load, or patients with clinical lymph node positivity or tumour size of 2cm and above.) 5. ECOG performance status 0-1. 6. 6. LVEF ≥ 55% 7. 7. Adequate bone marrow functional reserve: white blood cell count ≥3.0 x 109/L, neutrophil count ≥1.5 x 109/L; and 1.5 x 109/L; platelet count ≥ 100 x 109/L; haemoglobin ≥ 90 g/L; 8. AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value. Total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value. 9. For non-menopausal or non-surgically sterilised female patients: during treatment and at least 7 months after the last dose of study treatment. For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of study treatment. Exclusion Criteria: 1. Contraindication to hyperbaric oxygen therapy: untreated pneumothorax. Concurrent use of disulfiram. concomitant administration of anti-tumour drugs such as bleomycin, cisplatin, adriamycin concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. Premature and/or low body mass neonates. Lung disease (severe chronic obstructive pulmonary disease). Diseases of the lungs (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, uncontrolled diarrhoea). controlled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube Dysfunction of the eustachian tube, recurrent episodes of vertigo), ocular disease (retinal detachment). 2. previous hyperbaric oxygen therapy. 3. distant metastases, including lymph node metastases to the contralateral breast and mediastinum. 4. other malignant tumours within the last two years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. Tumour. 5. pregnancy or lactation 6. uncontrolled hypertension, cardiac, hepatic, renal related disease or other medical or psychiatric conditions. 7. major surgical procedure unrelated to breast cancer within 4 weeks prior to randomisation, or the patient has not fully recovered from such procedure; or has not fully recovered from such surgical intervention. 8. serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to Serious or uncontrolled infections that may interfere with study treatment or the evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, and pulmonary infections. 9. recent history of thromboembolism and taking full dose anticoagulant medication. 10. any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study

Inclusion Criteria: 1. Female patients, aged 18-75 years old; The pregnancy test (-) and reliable contraceptive methods are required for premenopausal and perimenopausal patients; 2. Patients with the diagnosed breast cancer confirmed by core needle biopsy and unilateral operation was performed; Breast cancer patients with tumor node metastasis stage 0-III according to the 8th edition of the American Joint Commission on Cancer; Preoperative clinical examination or imaging evaluation shows that the distance between the tumor and the Nipple Areolar Complex (NAC) is more than 1cm. The tumor has a diameter of 2-3 cm and can be located in any quadrant or reduced to 3 cm through preoperative neoadjuvant chemotherapy. The distance between the lesion and the skin should be at least 8-10 mm; 3. There is no clinical or imaging evidence to prove that the tumor has invaded the skin, chest wall, or nipple areola complex; 4. There are indications for breast preservation, but the patient has a strong desire for reconstruction and is unwilling to undergo breast preservation surgery; 5. Preventive mastectomy (BRCA1/2 malignant mutation with obvious family history of breast cancer and other high-risk groups); 6. Preoperative clinical manifestations and imaging data showed no distant metastasis; 7. No history of breast cancer or other serious underlying diseases in the past; 8. Karnofsky performance status score ≥ 70; 9. Eastern Cooperative Oncology Group score ≤ 2 ; 10. The surgical procedure includes endoscopic-assisted/conventional mastectomy, sentinel lymph node biopsy/axillary lymph node dissection and immediate breast reconstruction; 11. Participants are able to understand the research process, voluntarily join the study, sign informed consent forms, have good compliance, and cooperate with follow-up; 12. No swallowing difficulties; No shoulder joint movement disorders; 13. Complete clinical data. Exclusion Criteria: 1. Male breast cancer or inflammatory breast cancer; 2. Metastatic breast cancer (stage IV); Tumor invasion of the skin, pectoralis major muscle, or NAC; 3. The clinical data is basically incomplete; 4. Previously received chemotherapy in an external hospital or has undergone tumor resection in an external hospital; 5. Bilateral breast cancer surgery; 6. Other surgical methods; 7. Preoperative distant metastasis or supraclavicular lymph node dissection; 8. Complicated with other malignant tumors or had malignant tumors other than breast cancer in recent 5 years; 9. The serious disease of non malignant tumors combined will affect the patient's compliance or put the patient in a dangerous state; 10. Dementia, intellectual disability, or any mental illness that hinders understanding of informed consent forms.

Inclusion Criteria: \- Female, aged ≥ 18 years. Pathologically confirmed diagnosis of breast cancer. Patients who received immunotherapy/neoadjuvant immunotherapy at our institution between January 1, 2015, and September 30, 2023 (retrospective cohort), or patients who may receive immunotherapy/neoadjuvant immunotherapy starting from October 1, 2023 (prospective cohort). Availability of sufficient tumor tissue samples (e.g., fresh biopsy tissue, residual tumor tissue post-surgery). Availability of blood samples and imaging data. Signed informed consent (for the prospective cohort). Exclusion Criteria: * Male breast cancer patients. Inability to provide sufficient tumor tissue samples or other clinical data. Presence of severe comorbidities (e.g., active infections, severe cardiac, hepatic, or renal dysfunction) that may affect the safety assessment of immunotherapy. Lack of signed informed consent (for the prospective cohort).

A. Inclusion Criteria: * able to understand treatment protocol and informed consent form * estimated by the investigator to be compliant for study participation 1\. Fulfilling all group-specific inclusion criteria: * confirmed breast cancer with an indication to undergo breast conserving surgery * confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy; * confirmed thyroid lesion with an indication to undergo resective surgery; * confirmed parathyroid adenoma with an indication to undergo resective surgery; * suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery; * suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery; * suspected lesion in the head \& neck region with an indication to undergo resective surgery; * confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery; * patients undergoing biopsy after metabolic active lesions were detected on a PET scan. * suspected neuro-endocrine malignancies with an indication to undergo resective surgery. * suspected brain tumor with an indication to undergo resective surgery. * Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery. * suspected malignant thoracovascular lesions with an indication to undergo resective surgery B. Exclusion Criteria: * general or local contra-indications for resective surgery; * in case of FDG-based PET tracers: a blood glucose level over 200 mg/dL on the day of surgery; * pregnancy or lactation; * participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.

Inclusion Criteria: * Participant is assigned female or male at birth. * Participant is aged between 21 to 65 years, inclusive, at Screening. * Participant has a BMI of 18 to 30 kg/m2, inclusive, at Screening. * Participant is ≥60 kg. * Participant has a diagnosis of MDD (as defined in the DSM-5 established through a clinician interview that includes the Mini-International Neuropsychiatric Interview) * Depression severity moderate to severe based on MADRS score ≥21. * Anxiety severity moderate to severe based on GAD-7 ≥10. * Inadequate response to current antidepressant medication in current episode of depression. * Participant has been on a stable dose (no more than 50% change) of antidepressant medication (SSRI or SNRI) in the last month prior to Screening. * Participants capable of producing sperm must use a condom during the trial and for 3 months after their dose of trial medication, if their partner is a person of childbearing potential. In addition, their partner of childbearing potential must use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) from dosing until 3 months following dosing. * Participants of childbearing potential must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with use of a condom by a partner who is capable of producing sperm, during the trial and for 3 months after dosing. Such participants must have a negative pregnancy test at Screening and Day 1. * Participants of non-childbearing potential who are or were capable of producing eggs (ova) must be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy or bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle stimulating hormone (FSH) level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception. * Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Exclusion Criteria: * A reduction in the MADRS score of 25% or more between Screening and Baseline. * Failure to respond to \>2 antidepressant treatments given at an adequate dose for an adequate duration during the current episode of depression. * Current or previously diagnosis of schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder (as determined by MINI at Screening). * Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview that incorporates the Columbia Suicide Severity Rating Scale (CSSRS); a score of 4 or higher on the suicidal ideation subscale of C-SSRS (past 6 months) or any suicidal behaviour (lifetime), would be exclusionary. * History of substance use disorder within the 12 months, as assessed by a structured clinical interview (Mini International Neuropsychiatric Interview \[MINI\], Version 7.0.2) or determined by self-report, or intake of \>21 units of alcohol weekly, and the inability to refrain from alcohol use from 48 hours before Screening and each scheduled visit until discharge from the study site. One unit is equivalent to a 285 mL glass of full-strength beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine. * Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, other non-SSRI or non-SNRI antidepressants (e.g. bupropion, mirtazapine, etc), an antipsychotic or a mood stabilizer. * Exposure to psilocin, or any other psychedelics, such as ayahuasca, mescaline, LSD or peyote more than 10 times in the last 10 years, or any psychedelic use within 6 months prior to Screening. * Use of psychotropic medicine/supplement (or medicine/supplement that would interact with psilocybin) during the 28 days before dosing. Participants may take a stable chronic dose of antidepressant medication(s) and/or sedatives/hypnotics. The Investigator and study team may review medication on a case-by-case basis to determine if its use would compromise participant safety or interfere with study procedures or data interpretation. * Family history of schizophrenia or schizoaffective disorder (first degree relatives), or bipolar disorder type 1 (first degree relatives). * Clinically relevant history of abnormal physical health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including but not limited to, neurological, endocrine, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder). * Participant has a presence or relevant history of any of the following medical conditions: organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions). * Diagnosis of hypertension or arrhythmia. * Clinically relevant abnormal heart rate (resting supine heart rate \>100 bpm) or blood pressure (resting supine systolic blood pressure (SBP) above 140 mmHg or diastolic blood pressure (DBP) above 90 mmHg) at screening. Screening supine SBP, DBP and heart rate for evaluation will be the average of 3 readings obtained after at least 5 minutes rest. Participants with abnormal vital signs which are out of range and deemed clinically significant by the Investigator at Day 1, following triplicate readings. * Presence of clinically significant ECG abnormalities at the Screening visit, as defined by medical judgement. * QT interval corrected for heart rate using Fridericia's formula (QTcF) \>450 msec at Screening, following triplicate ECG readings. * Hypothyroidism and/or current abnormal thyroid function tests. In case of uncertain or questionable screening thyroid function test results, the TSH test may be repeated once during screening. The TSH test must be reviewed to ensure that it is within normal limits before randomizing a participant into the study. * Clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), 12-lead ECG and vital signs, or physical findings at Screening. In case of uncertain or questionable results, tests performed during Screening may be repeated once to confirm eligibility or judged to be clinically irrelevant. * Other eligibility considerations (i.e., participant personal circumstances, behavior, and/or any current problem that might interfere with participation or that is incompatible with establishment of rapport or safe exposure to psilocin), as judged by the Investigator. * History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion (ADME) of the study drug. * Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study. * Participant is not fluent in English. * Aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT) or total bilirubin levels ≥1.5 x the upper limit of normal (ULN) at Screening. These laboratory evaluations may be repeated once at the discretion of the Investigator. If the repeat test is within the reference range, the participant may be included if the Investigator considers that the previous finding will not introduce additional risk factors. * Positive urine test

Inclusion Criteria: 1. Signed Informed consent at study entry; 2. Age: 30-70 years; 3. T2DM diagnosis according to the American Diabetes Association criteria since ≥6 months; 4. Stable metabolic control as indicated by levels of glycated hemoglobin (HbA1c) \<7.5% on two consecutive measurements before study enrollment; 5. Body mass index (BMI) level ≥30 Kg/m2 during the 3 months preceding randomization. Exclusion Criteria: 1. Chronic treatment with corticosteroids and/or chronic treatment with non-steroidal inflammatory drugs, defined as ≥3 times/week with the rationale that these drugs independently impact on the whole inflammatory state; 2. Clear indication for dual antiplatelet therapy and/or anticoagulant therapy (full dose); 3. Active cancer or cancer in complete remission from less than one year, except for treated early-stage squamous or basal cell skin carcinomas; 4. For women with childbearing potential, pregnancy.

Inclusion Criteria: * childern age from 6 to less than 18 * childern with simple and complex CHD * in patient and out patient childern * preoperative and postoperative patient Exclusion Criteria: * patient indicated for icu * patient with critical arrythmias * caregiver refuse to participate in the study

Inclusion Criteria: 1. Understand the study process, participate in the study voluntarily, and sign the informed consent form. 2. have an initial histopathologically confirmed diagnosis of unilateral primary invasive breast cancer, excluding occult breast cancer, inflammatory breast cancer and eczema-like carcinoma 3. aged ≥ 18 years and ≤ 60 years, female 4. patients who meet the inclusion criteria of neoadjuvant therapy to receive neoadjuvant therapy for breast cancer (patients with locally advanced breast cancer (AJCC Stage III, except T3N1M0) or operable but not in breast-conserving or axillary-sparing condition (Stage IIA-IIB and T3N1M0), or patients with a certain tumour load of HER2-positive or TNBC with clinical lymph node positivity, or patients with a tumour size of 2cm and above). or tumour size 2cm and above). 5. ECOG performance status 0-1. 6. LVEF ≥ 55% 7. Adequate bone marrow functional reserve: white blood cell count ≥3.0 x 109/L, neutrophil count ≥1.5 x 109/L; platelet count ≥100 x 109/L; haemoglobin ≥90 g/L; 8. AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value 9. For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of the study treatment \- Exclusion Criteria: 1. Contraindication to hyperbaric oxygen therapy: untreated pneumothorax. Concurrent use of disulfiram. concomitant administration of anti-tumour drugs such as bleomycin, cisplatin, adriamycin concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. Premature and/or low body mass neonates. Lung disease (severe chronic obstructive pulmonary disease). Diseases of the lungs (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, uncontrolled diarrhoea). controlled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube Dysfunction of the eustachian tube, recurrent episodes of vertigo), ocular disease (retinal detachment). 2. previous hyperbaric oxygen therapy. 3. distant metastases, including lymph node metastases to the contralateral breast and mediastinum. 4. other malignant tumours within the last two years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. Tumour. 5. pregnancy or lactation 6. uncontrolled hypertension, cardiac, hepatic, renal related disease or other medical or psychiatric conditions. 7. major surgical procedure unrelated to breast cancer within 4 weeks prior to randomisation, or the patient has not fully recovered from such procedure; or has not fully recovered from such surgical intervention. 8. serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to Serious or uncontrolled infections that may interfere with study treatment or the evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, and pulmonary infections. 9. recent history of thromboembolism and taking full dose anticoagulant medication. 10. any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study

Inclusion Criteria: 1. Male or female subjects over 18 years of age. 2. The subject must have a solid tumor confirmed by histology or cytology, and belong to one of the following categories: 1) locally advanced or metastatic SCLC, which has received standard treatment in the past and developed progress or intolerance; 2) Low-grade, medium-grade or high-grade locally advanced or metastatic GEP-NET, who has previously received first-line or multi-line anti-tumor treatment and developed progress or intolerance (unless there is no standard treatment available or such treatment is not suitable); 3) Metastatic or locally advanced unresectable TNBC, which is confirmed by histological examination, is characterized by the lack of expression of human epidermal growth factor 2(HER2), estrogen receptor (ER) and progesterone receptor (PR), and recurs/is refractory after standard treatment or has no standard treatment (which must include paclitaxel chemotherapy). 4) Other locally advanced or metastatic solid tumor subjects who have failed or are intolerant of standard treatment. 3. ECOG PS is 0-1. 4. Life expectancy ≥3 months. 5. Organ function is normal, which is defined as follows: 1) Bone marrow (not treated with blood transfusion or hematopoietic stimulating factors within 14 days): absolute neutrophil (ANC) ≥ 1.5× 10 9/L, platelet count ≥ 100× 10 9/L, hemoglobin ≥ 90 g/L. 2) Liver: total bilirubin (TBIL) ≤1.5× upper limit of normal value (ULN), or TBIL\>1.5×ULN with direct bilirubin (DBIL) ≤ ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤3×ULN (≤5×ULN if accompanied by liver metastasis). 3) Kidney: serum creatinine concentration ≤1.5×ULN or creatinine clearance ≥50 mL/min(Cockcroft-Gault formula) 4) Coagulation function: partial thromboplastin activation time (APTT) or ≤ 1.5× ULN; International normalized ratio (INR) or prothrombin time (PT)≤1.5×ULN (INR\<3.0 if the subject uses anticoagulant). 6. Detection requirements for biomarkers: 1) For the dose escalation and backfill cohort in Phase I study, biomarkers are not detected when they are selected, and the subjects need to provide archived or fresh tumor tissues within 2 years (if the archived tissue samples are more than 2 years and fresh tumor tissues are difficult to obtain, they can communicate with the applicant to decide whether to exempt them); During the study, the biomarker detection results of subjects in the follow-up dose expansion cohort may be added as additional selection criteria according to the obtained clinical data; 2) For Phase II study, the subjects should provide archived or fresh tumor tissues within 2 years (if the archived tissue samples are more than 2 years and fresh tumor tissues are difficult to obtain, they can communicate with the sponsor to decide whether to exempt them), and at baseline, the biomarkers should be detected by IHC in the central laboratory. 7. According to the RECIST version 1.1 standard, there is at least one target lesion (the target lesion must have not received radiotherapy before, or there is clear evidence of disease progression after radiotherapy). 8. Male or female subjects who are infertile, not in pregnancy or agree to use at least one effective contraceptive method during the study intervention period (from 14 days before the first administration to at least 180 days after the last administration of the study intervention) are eligible to participate in the study, and abide by the following contents: 1) Avoid donating fresh unwashed sperm or eggs. 2) Women who are breastfeeding should stop breastfeeding during the study period. 9. An informed consent form (ICF) that can be understood and signed, including compliance with ICF and the requirements and restrictions listed in this plan. Exclusion Criteria: 1. According to the researcher's judgment, there are serious or poorly controlled systemic diseases, active bleeding tendency, renal transplantation or liver transplantation, active infection, including syphilis-specific antibody or human immunodeficiency virus (HIV) antibody positive, or active hepatitis B (hepatitis B surface antigen positive and/or core antibody positive and HBV-DNA copy number \> 1000 copies /ml or \> 200 IU/ml) or hepatitis C (C). 2. Suffering from other malignant tumors within 3 years before the first administration, except those who have received adequate treatment: 1) Cervical cancer in stage 1B or below. 2) Non-invasive basal cell or squamous cell skin cancer. 3) Non-invasive superficial bladder cancer. 4) Prostate cancer, the current PSA level is less than 0.1 ng/ mL. 3. Meet one or more of the following cardiac criteria: 1) Severe or unstable angina pectoris; 2) Myocardial infarction, coronary artery or peripheral artery bypass grafting, stroke or transient ischemic attack and symptomatic orthostatic hypotension occurred within 6 months before screening; 3) new york Heart Association II-IV heart failure; 4) QT interval (QTc) corrected by Fredericia formula at baseline: male \> 450 msec, female \> 470 msec；; 5) There are serious abnormalities in heart rhythm, conduction or morphology (for example, complete left bundle branch block, third degree heart block); 6) Congenital long QT syndrome; 7) Hypertension that is still poorly controlled after antihypertensive treatment (it needs to be measured three times continuously, that is, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg). 4. Received major surgery within 28 days before C1D1. 5. There are unstable brain metastases with clinical symptoms and/or a history of meningeal diseases, brain stem or spinal cord compression. Subjects who have no clinical symptoms and have ≤3 metastatic lesions, and the largest lesion diameter is \< \<0.5cm, or whose symptoms are stable after treatment and do not need hormone drugs, can enter the study if they meet all the following criteria: (1) There are other measurable lesions besides the central nervous system; (2) New or expanded metastatic foci that have been in a stable state for at least 4 weeks without clinical evidence. If whole brain radiotherapy has been performed, it is at least 28 days before the first administration; If it is stereotactic radiosurgery or stereotactic radiotherapy, it is at least 14 days before the first administration. 6. Have a life-threatening trauma with increased risk of bleeding or a history of severe head trauma or intracranial surgery within 2 months before enrollment. 7. There is clear imaging evidence of tumor cavity or large blood vessel invasion, and the tumor is adjacent to important blood vessel structures, and the researcher judges that there is a risk of fatal bleeding. 8. Peripheral motor neuropathy or peripheral neuropathy with CTCAE grade ≥2 exists. 9. There are active viral, bacterial or fungal infections with clinical significance, which need the following treatment: 1) start intravenous antibacterial treatment within 4 weeks before the first administration, or 2) start oral antibacterial treatment within 10 days before the first administration. 10. Suffering from inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. 11. Pneumonia ≥ 3 or clinically significant lung diseases, such as interstitial lung disease, non-infectious pneumonia, radiation pneumonia, pulmonary fibrosis, acute lung injury, etc.; Moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring long-term drug treatment. 12 suffering from acute or chronic inflammatory skin diseases that have not yet recovered. 13\. Have a history of deep venous thrombosis, pulmonary embolism or other serious venous thromboembolism within 3 months before the first administration (implantable venous access or catheter-derived thrombosis or superficial venous thrombosis is not considered as serious venous thromboembolism). 14\. There is pelvic cavity, abdominal cavity, chest cavity or pericardial effusion that needs intervention, which can be

Inclusion Criteria: * Diagnosed with Type 2 diabetes according to the 1999 WHO criteria * Aged ≥18 years * UACR ≥30 mg/g and eGFR ≥30 ml/min/1.73 m² sustained for over 3 months * Stable ARB/ACEI treatment for ≥4 weeks prior to enrollment * Willing to sign a written informed consent and comply with the study protocol Exclusion Criteria: * Chronic kidney disease diagnosed before Type 2 diabetes * Serum potassium \>4.8 mmol/L * Ineffective blood pressure control at screening (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg, average of three measurements in the supine position) * HbA1c \>9% * Acute urinary tract infection or conditions affecting urine tests * Primary or secondary adrenal insufficiency * Use of mineralocorticoid receptor antagonists * Use of medications with clear effects on urine protein and eGFR within 4 weeks (except kininogenase) * Use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, nefazodone, carbamazepine) * ALT or AST \>2.5 × ULN, total bilirubin (TBIL) \>2 × ULN * Use of systemic glucocorticoids for more than 7 days within 12 weeks prior to screening, or use of systemic glucocorticoids (intravenous/oral or intra - articular) or need for systemic immunosuppressive treatment within the past 14 days * Any organ system cancer within the past 5 years, whether treated or untreated * Known pregnancy (positive pregnancy test), breastfeeding, recent plans for conception, or not using adequate contraception * Participation in other interventional clinical trials within 3 months prior to screening

Inclusion Criteria: * Any general practitioner or nurse working in a primary care practice. * Having enough clinical activity to be included in the pay-for-performance schemes by the PCP director. * Belonging to a PCP in the regions of Catalunya Central, Penedès or Girona. * Belonging to a PCP whose director accepted to participate in the study. Exclusion Criteria: * PCPs with very low overall quality-of-care scores (\<60%). * Professionals who did not sign the pay-for-performance contracts.